Page 60 - Read Online

Page 10 of 11 Kanmaniraja et al. Hepatoma Res 2020;6:51 I http://dx.doi.org/10.20517/2394-5079.2020.46

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
Chernyak V is the consultant for Bayer; Kanmaniraja D declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2020.

REFERENCES
1. GLOBOCAN International Agency for Research on Cancer (IARC). Available from: https://gco.iarc.fr/. [Last accessed on 7 July 2020]
2. World Health Organization Mortality Database. WHO Statistical Information System. 2008. Available from: https://www.who.int/news-
room/fact-sheets/detail/cancer. [Last accessed on 7 July 2020].
3. Petrick JL, Kelly SP, Altekruse SF, McGlynn KA, Rosenberg PS. Future of hepatocellular carcinoma incidence in the United States
forecast through 2030. J Clin Oncol 2016;34:1787-94.
4. Petrick JL, Braunlin M, Laversanne M, Valery PC, Bray F, et al. International trends in liver cancer incidence, overall and by histologic
subtype, 1978-2007. Int J Cancer 2016;139:1534-45.
5. Tang A, Bashir MR, Corwin MT, Cruite I, Dietrich CF, et al. Evidence supporting LI-RADS major features for CT- and MR imaging-
based diagnosis of hepatocellular carcinoma: a systematic review. Radiology 2018;286:29-48.
6. Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018
Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2018;68:723-50.
7. Chernyak V, Fowler KJ, Kamaya A, Kielar AZ, Elsayes KM, et al. Liver imaging reporting and data system (LI-RADS) Version 2018:
imaging of hepatocellular carcinoma in at-risk patients. Radiology 2018;289:816-30.
8. The American College of Radiology LI-RADS v2018 Core. Available from: https://www.acr.org/-/media/ACR/Files/RADS/LI-RADS/LI-
RADS-2018-Core.pdf?la=en. [Last accessed on 29 Jun 2020]
9. Chapter-8-LIRADS-Categories. ACR. Available from: https://www.acr.org/-/media/ACR/Files/Clinical-Resources/LIRADS/Chapter-8-
LIRADS-Categories.pdf?la=en. [Last accessed on 29 Jun 2020]
10. Roberts LR, Sirlin CB, Zaiem F, Almasri J, Prokop LJ, et al. Imaging for the diagnosis of hepatocellular carcinoma: a systematic review
and meta-analysis. Hepatology 2018;67:401-21.
11. Basha MAA, AlAzzazy MZ, Ahmed AF, Yousef HY, Shehata SM, et al. Does a combined CT and MRI protocol enhance the diagnostic
efficacy of LI-RADS in the categorization of hepatic observations? A prospective comparative study. Eur Radiol 2018;28:2592-603.
12. Corwin MT, Fananapazir G, Jin M, Lamba R, Bashir MR. Differences in liver imaging and reporting data system categorization between
MRI and CT. AJR Am J Roentgenol 2016;206:307-12.
13. Tang A, Hallouch O, Chernyak V, Kamaya A, Sirlin CB. Epidemiology of hepatocellular carcinoma: target population for surveillance
and diagnosis. Abdom Radiol (NY) 2018;43:13-25.
14. Chernyak V, Tang A, Flusberg M, Papadatos D, Bijan B, et al. LI-RADS((R)) ancillary features on CT and MRI. Abdom Radiol (NY)
2018;43:82-100.
15. Santillan C, Chernyak V, Sirlin C. LI-RADS categories: concepts, definitions, and criteria. Abdom Radiol (NY) 2018;43:101-10.
16. Chapter-11-Management. ACR. Available from: https://www.acr.org/-/media/ACR/Files/Clinical-Resources/LIRADS/Chapter-11-
Management.pdf?la=en. [Last accessed on 29 Jun 2020]
17. van der Pol CB, Lim CS, Sirlin CB, McGrath TA, Salameh JP, et al. Accuracy of the liver imaging reporting and data system in
computed tomography and magnetic resonance image analysis of hepatocellular carcinoma or overall malignancy-a systematic review.
Gastroenterology 2019;156:976-86.
18. Mitchell DG, Bruix J, Sherman M, Sirlin CB. LI-RADS (Liver Imaging Reporting and Data System): summary, discussion, and
consensus of the LI-RADS Management Working Group and future directions. Hepatology 2015;61:1056-65.
19. Fowler KJ, Potretzke TA, Hope TA, Costa EA, Wilson SR. LI-RADS M (LR-M): definite or probable malignancy, not specific for
hepatocellular carcinoma. Abdom Radiol (NY) 2018;43:149-57.